tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Boston Scientific Acurate TAVR discontinuation a positive, says Barclays

Barclays analyst Matt Miksic says the discontinuation of the Acurate TAVR program at Boston Scientific (BSX) “should not come as a surprise to investors” given the failure to meet its non-inferiority endpoint last year. The firm views the news as “an incremental positive for the stock” as management will reallocate resources to innovative programs with greater potential for higher returns. The firm, which also notes that management reaffirmed its Q2 and 2025 outlook for reported, organic sales, and adjusted EPS, reiterates an Overweight rating and $125 price target on Boston Scientific shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1